Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP961779priorityCriticalpatent/ECSP961779A/en
Publication of ECSP961779ApublicationCriticalpatent/ECSP961779A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
El invento se refiere a un procedimiento para minimizar el efecto de la pérdida ósea de un compuesto de fórmula II (gráfico) o una de sus sales farmacéuticamente aceptable, en la que dicho compuesto de fórmula II se administra a un mamífero en necesidad de tratamiento, que comprende administrar de forma concurrente o secuenciual a dicho mamífero una cantidad eficaz de un compuesto de fórmula I. (gráfico), en la que cada R1 es independientemente -H, -OH, -(alquilo de C1-C4), OCOC6H5, -OCO(alquilo de C1-C6) U -OSO2( alquilo de C4, C6); y R2 es 1-piperidinilo, 1-pirrolidinilo, metil-1-pirrolidinilo, dimetil-1- pirrolidinilo, 4-morfolino dimetilamino, dietilamino o 1 -hexametilenimino; o una de las sales farmacéuticamente aceptables del mismo. También se proporciona un procedimiento para minimizar la perdida ósea inducida por la administración de un compuesto de fórmula II que comprende administrar de una forma concurrente o secuencial un agente anabólico óseo. También se proporcionancomposiciones farmacéuticas.The invention relates to a method of minimizing the bone loss effect of a compound of formula II (graph) or a pharmaceutically acceptable salt thereof, wherein said compound of formula II is administered to a mammal in need of treatment, comprising administering concurrently or sequentially to said mammal an effective amount of a compound of formula I. (graph), wherein each R1 is independently -H, -OH, - (C1-C4 alkyl), OCOC6H5, - OCO (C1-C6 alkyl) U -OSO2 (C4, C6 alkyl); and R2 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino dimethylamino, diethylamino or 1-hexamethyleneimino; or one of the pharmaceutically acceptable salts thereof. A method is also provided to minimize bone loss induced by administration of a compound of formula II which comprises administering a bone anabolic agent concurrently or sequentially. Pharmaceutical compositions are also provided.
ECSP9617791996-06-061996-06-06
PROCEDURES TO MINIMIZE LOSS OSEA X-10221
ECSP961779A
(en)
DERIVATIVES OF NAFTIRIDINES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AN INFLAMMATORY DISEASE
THENOPYRIMIDINES, A PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL PREPARATIONS THAT CONSTITUTE THEM AND A PROCEDURE TO OBTAIN THESE PHARMACEUTICAL PREPARATIONS
PROCEDURE FOR PREPARING COMPOUNDS OF 2-PHENYL-3-PHENOXY OR PHENYLTIO-BENZOTIOFEN AND PHARMACEUTICALLY ACCEPTABLE SALTS, INTERMEDIATE COMPOUNDS OF EXCLUSIVE APPLICATION IN SUCH PROCEDURE AND METHOD FOR PREPARING INTERMEDIATE COMPOUNDS
CYCLOHEXILO COMPOUND, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, DIAGNOSTIC AGENT, PHARMACEUTICAL COMPOSITION CONTAINING IT, PROCESS FOR PREPARATION, COMPOUNDS FOR ITS EXCLUSIVE USE IN THE PREPARATION OF SUCH CYCLODOOD METHODOIL COMPOUNDS,
USE OF (+) -ALFA- (2,3-DIMETOXIFENIL) -1- [2- (4-FLUOROPHENYL) ETHYL] -4-PIPERIDINMETHANOL OR ITS DRUG FOR THE MANUFACTURE OF A MEDICINAL PRODUCT IN THE TREATMENT OF SYMPTOMS OF DEMENTIA AND OF PSYCHOSIS INDUCED BY DOPAMINE
1,4-REPLACED PHENYL COMPOUND, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, DIAGNOSTIC AGENT, PHARMACEUTICAL COMPOSITION CONTAINING IT AND PROCESS FOR PREPARATION